Chelsie Derman

The study found that, following gradual policy changes, children with acute liver failure requiring a transplant now face a reduced risk of both mortality and graft failure from 1989.

A new study highlights suboptimal HDV screening rates in HBV-infected individuals, suggesting that treating HBV may improve survival for those with HDV coinfection.

A study found that migraine-related disability worsens health-related quality of life, with gender-specific differences, particularly affecting women with mild disability.

Phase 3 data found 66.5% of people with migraine attacks treated with STS101 had headache pain relief two hours after the dose.

A meta-analysis revealed taking pregabalin with supplement vitamin D reduced migraine frequency in children by 88%

A study finds CGRP monoclonal antibodies are not clinically superior to topiramate or Botox in treating chronic migraines, raising cost-effectiveness concerns.

Xanomeline trospium chloride offers a new pathway in schizophrenia treatment, improving cognitive symptoms without D2 receptor-related side effects like tardive dyskinesia.

HCPLive spoke with Monroe regarding muscarinic modulators, both the ones in development and xanomeline trospium chloride capsules (Cobenfy).

Comorbid migraine and insomnia are linked to altered locus coeruleus connectivity, suggesting it is a biomarker for sleep disturbances and a potential therapeutic target.

A meta-analysis shows that wet cupping reduces migraine intensity but doesn't improve quality of life. Adjunctive therapies offer limited additional benefits.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

A study of > 14,000 patients offers insights on real-world usage and characteristics of new rimegepant users, showing distinct patterns in acute vs. preventive treatment.

A study shows secukinumab clears skin lesions faster than ustekinumab in generalized pustular psoriasis, with improved responses observed by week 2.

Crisugabalin at 40 mg/d or 80 mg/d significantly reduced daily pain in adults with postherpetic neuralgia, a phase 3 study found.

Triptans, including eletriptan and sumatriptan, offer better migraine relief than newer, more expensive drugs, suggesting they should be first-line treatments.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

A recent study found that after 2019, the combined cost of fatal falls among people aged ≥ 45 exceeded firearm injury costs, highlighting the economic burden of senior falls.

The AI model, SLIViT, improves accuracy and efficiency in interpreting 3D medical scans, outperforming traditional methods and reducing specialists' workload.

A study links conversion therapy with worse mental health, such as PTSD and depression, showing a need for legislative action and support for LGBTQ+ individuals.

This Month in Review features the approval of trospium chloride capsules (Cobenfy) as well as other clinical trials in the psychiatry field.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

A study found pregnant patients with IgA nephropathy and adverse pregnancy outcomes were less likely to achieve proteinuria remission, though renal function remained unaffected.

HCPLive spoke to Rodriguez, MD, MPH, about implementing AI in cardiology care.

At the Family Heart Global Summit 2024, Bhatia spoke about the importance of universal Lp(a) screening over only targeted screening.

In an interview O’Donoghue talked about emerging RNA therapies for Lp(a) in phase 2 and 3 trials.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

HCPLive spoke to Johnson on how strategies for addressing patient misconceptions about cholesterol management.

At the Family Heart Summit, Nihar Desai, MD, discussed using EMR alerts to improve lipid therapy for high-risk ASCVD, as shown in the PROMPT-Lipid trial.

The analysis of LDL-C Management Trends observed disparities in LDL-C goal attainment by race, gender, and age.